Kexing Biopharm (688136.SH) terminates clinical trial of recombinant human interferon 2b nasal spray.
Kexing Pharmaceutical (688136.SH) announced that the company's research and development of interferon 2b spray is in the clinical research stage.
Kexing Biopharm (688136.SH) announced that the company's development of interferon 2b nasal spray is in the clinical research stage. Recently, after careful consideration of the drug's future development risks, the company has decided to terminate the clinical trials of this project.
Related Articles
Bidding for Warner Bros. (WBD.US) enters a critical period, while Paramount Skydance (PSKY.US) speeds up the antitrust review process.
US Stock Market Move | Multiple departments issued letters to support the new consumption and financial consumption driving LexinFintech Holdings Ltd. Sponsored ADR Class A (LX.US) to rise by 6.04%.
Industry's First Rider Family Hospitalization Protection Implemented Meituan Upgrades Major Illness Care Plan Covering Over One Million Rider Families
Bidding for Warner Bros. (WBD.US) enters a critical period, while Paramount Skydance (PSKY.US) speeds up the antitrust review process.
US Stock Market Move | Multiple departments issued letters to support the new consumption and financial consumption driving LexinFintech Holdings Ltd. Sponsored ADR Class A (LX.US) to rise by 6.04%.
Industry's First Rider Family Hospitalization Protection Implemented Meituan Upgrades Major Illness Care Plan Covering Over One Million Rider Families
